# US 2005/0033034 A1 · Anti-t cell immunotoxin fusion protein and its therapeutic use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0033034 A1
- Document ID: US20050033034A1
- Status: Published application
- Kind: A1
- Application number: 10/496,179
- Filed: 2002-11-27
- Published: 2005-02-10
- Earliest claimed: 2001-11-28
- Inventors: Gunter Engel
- Web page: https://patentgrep.com/patent/US20050033034A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 39/39541: {against normal tissues, cells}
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/21: from Pseudomonadaceae (F)
- C07K 14/34: from Corynebacterium (G)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A combination comprising (a) an anti-T cell immunotoxin fusion protein comprising (i) a diphtheria or Pseudomonas toxin moiety and (ii) a targeting moiety suitable for targeting the fusion protein to T cells and (b) at least one chemotherapeutic agent.

## Claims

### Claim 1

A combination comprising:
(a) an anti-T cell immunotoxin fusion protein comprising (i) a diphtheria or Pseudomonas toxin moiety and (ii) a targeting moiety suitable for targeting the fusion protein to T cells; and
(b) at least one chemotherapeutic agent comprising:
(i) an antineoplastic agent selected from the group consisting of:
aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase 11 inhibitors, microtubule active agents, busulfan, ifosfamide, melphalan, 5-fluorouracil, cytarabine, fludarabine, capecitabine, gemcitabine, edatrexate, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bisphosphonates, trastuzumab, 6-thioguanidine, hydroxyurea, procarbazine and bleomycin; or
(ii) an agent used as an adjuvant in cancer therapy.

### Claim 2

A pharmaceutical composition comprising:
(a) an anti-T cell immunotoxin fusion protein comprising (i) a diphtheria or Pseudomonas toxin moiety and (ii) a targeting moiety suitable for targeting the fusion protein to T cells; and
(b) at least one chemotherapeutic agent comprising:
(i) an antineoplastic agent selected from the group consisting of:
aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase 11 inhibitors, microtubule active agents, busulfan, ifosfamide, melphalan, 5-fluorouracil, cytarabine, fludarabine, capecitabine, gemcitabine, edatrexate, platin compounds, compounds decreasing the protein kinase activity and further anti-angiogenic compounds, gonadorelin agonists, anti-androgens, bisphosphonates, trastuzumab, 6-thioguanidine, hydroxyurea, procarbazine and bleomycin; or
(ii) an agent used as an adjuvant in cancer therapy.

### Claim 3 (depends on 1)

A combination according to claim 1, wherein the targeting moiety comprises an anti-CD3 antibody.

### Claim 4 (depends on 1)

A combination according to claim 1, wherein the targeting moiety comprises IL-2 or at least a portion of the binding domain thereof.

### Claim 5 (depends on 1)

A combination according to claim 1, wherein the anti-T cell immunotoxin fusion protein comprises a polypeptide having a sequence as defined in any one of SEQ ID NOs 1 to 7.

### Claim at position 6

6-9. (canceled)

### Claim 10 (depends on 1)

A method of treating a malignant proliferative disease in a subject in need thereof comprising administering to the subject a combination as defined in claim 1.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the malignant proliferative disease comprises a lymphoma or leukemia.

### Claim 12 (depends on 2)

A method of treating a malignant proliferative disease in a subject in need thereof comprising administering to the subject a pharmaceutical composition as defined in claim 2.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the malignant proliferative disease comprises a lymphoma or leukemia.

### Claim 14 (depends on 2)

A pharmaceutical composition according to claim 2, wherein the targeting moiety comprises an anti-CD3 antibody.

### Claim 15 (depends on 2)

A pharmaceutical composition according to claim 2, wherein the targeting moiety comprises IL-2 or at least a portion of the binding domain thereof.

### Claim 16 (depends on 2)

A pharmaceutical composition according to claim 2, wherein the anti-T cell immunotoxin fusion protein comprises a polypeptide having a sequence as defined in any one of SEQ ID NOs 1 to 7.

### Claim 17 (depends on 3)

A combination according to claim 3, wherein the anti-T cell immunotoxin fusion protein comprises a polypeptide having a sequence as defined in any one of SEQ ID NOs 1 to 7.

### Claim 18 (depends on 4)

A combination according to claim 4, wherein the anti-T cell immunotoxin fusion protein comprises a polypeptide having a sequence as defined in any one of SEQ ID NOs 1 to 7.

### Claim 19 (depends on 14)

A pharmaceutical composition according to claim 14, wherein the anti-T cell immunotoxin fusion protein comprises a polypeptide having a sequence as defined in any one of SEQ ID NOs 1 to 7.

### Claim 20 (depends on 15)

A pharmaceutical composition according to claim 15, wherein the anti-T cell immunotoxin fusion protein comprises a polypeptide having a sequence as defined in any one of SEQ ID NOs 1 to 7.
